| Ytd | -16.93% | |
| 1y | -16.93% |
| Open | 12.26 | Prev Close | 12.08 | Low | 11.63 | High | 12.99 | Mkt Cap | 599.35M |
| Vol | 250.67K | Avg Vol | 125.09K | EPS | -1.56 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 13.29 | 200-d Avg | 12.67 | 1yr Est | 0.00 |
AGMB News
Agomab Therapeutics targets fibrotic strictures in Crohn's disease, aiming to create a new treatment
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- --
Agomab announced shareholders approved all resolutions submitted for consideration at the Company's
Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-s
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiati
Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Chec
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on AgomAb Therapeutics (NASDAQ:AG
Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"
-- Regulatory alignment with U. S. Food and Drug Administration (FDA) on key elements of NOV-ERA Pha
B. Riley Securities analyst William Woods initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB)
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phas
-- Regulatory alignment with U. S. Food and Drug Administration (FDA) on key elements of NOV-ERA Pha
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top analysts changed ratings on top stocks, including Conexeu, CRDO, AGMB, SPCX, and FTH. See what a
HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on AgomAb Therapeutics (NA
AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drug
Antwerp, Belgium, May 27, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage
Antwerp, Belgium, May 14, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage
-- Cash and Cash Investments at December 31, 2025 of €116. 5 Million and Gross Proceeds of $208 Mill
Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutica
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“'Agomab'”), a clinical-st
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Rep
Leerink Partners analyst Thomas Smith initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) wit
JP Morgan analyst Anupam Rama initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Over
Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all change
Morgan Stanley analyst Judah Frommer initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are